Get expert stock market insights from Jigar Patel of Anand Rathi as he reveals why Oil India, Aurobindo Pharma, and Latent View Analytics present compelling short-term opportunities for Indian investors.
Indian biopharmaceutical leader Health Biotech Limited makes waves at CPhI Frankfurt 2025, showcasing innovative products and forging international partnerships to strengthen its global market position.
Nvidia CEO Jensen Huang declares the company as potentially the first technology firm in history to achieve such market dominance as it crosses the $5 trillion valuation mark.
Chandigarh-based Niner Pharma announces massive R&D expansion with 125 novel peptide molecules targeting wellness and cosmetic innovation, positioning India as global leader in peptide research.
Cipla's stock faced significant pressure after Q2 FY2025 results revealed margin pressures despite revenue growth. Discover the key factors behind the 4% decline and what analysts are saying about the pharmaceutical giant's future prospects.
Federal health officials are accelerating efforts to bring cheaper biotech drugs to market, potentially transforming treatment access and creating new opportunities for Indian pharmaceutical companies.
Cognizant Technology Solutions is actively exploring an initial public offering (IPO) in India, marking a significant strategic move that could reshape its relationship with the massive Indian market where it employs over 250,000 professionals.
Discover how Nvidia's strategic focus on artificial intelligence processors propelled it to a historic $5 trillion market valuation, reshaping the global tech landscape.
India implements sweeping regulatory reforms to combat fraudulent pharmaceutical manufacturing licenses, enhancing drug safety standards for domestic and international markets including US and EU.
Microsoft and OpenAI announce groundbreaking new agreement valuing the AI pioneer at a staggering $500 billion, marking one of the largest tech deals in history and setting new benchmarks for artificial intelligence valuation.
India's premier valuation firm 73 Strings partners with International Valuation Standards Council to host the prestigious 2025 AGM and International Valuation Conference in New Delhi, marking a significant milestone for India's financial sector.
Discover why prominent investor Mukul Agrawal is betting big on a small-cap pharma company with massive growth potential. Get exclusive insights into his latest portfolio move and what it means for retail investors.
Discover how Dr. Anji Reddy's visionary journey from generics to innovative drug research positioned India as a global pharmaceutical powerhouse and continues to inspire future generations.
In a revolutionary healthcare development, Bangladesh's Beximco Pharma launches affordable generic version of lifesaving rare disease drug, dramatically reducing treatment costs from crores to lakhs for patients across South Asia.
Sigachi Industries faces turbulent quarter with net profit crashing to ₹10.5 crore amid significant revenue decline. What's behind the pharmaceutical giant's disappointing performance?
Urban Company shares face massive sell-off as analysts flag overvaluation risks and predict additional 24% downside. Discover what's driving this home services giant's stock collapse.
Cipla's stock faces unexpected pressure despite securing rights to manufacture and distribute Eli Lilly's revolutionary weight loss drug Mounjaro in India. Discover why investors remain cautious.
Indian pharmaceutical giant Cipla announces landmark deal with Eli Lilly to manufacture and distribute popular weight loss medications Mounjaro and Zepbound in India under different brand names.
Indian pharma giant Aurobindo Pharma establishes new subsidiary in Chile, marking strategic expansion across South American markets with focus on branded prescriptions and over-the-counter medicines.
In a major pharmaceutical industry move, Torrent Pharmaceuticals receives Competition Commission of India approval to acquire controlling stake in JB Chemicals & Pharmaceuticals, marking significant consolidation in Indian pharma sector.
A significant legal triumph for India's pharmaceutical sector strengthens the position of generic drug makers against patent challenges. Explore how this ruling impacts affordable medicine production and India's role as the 'Pharmacy of the World'.
Danish pharma giant Novo Nordisk, the company behind diabetes & weight-loss blockbusters Ozempic and Wegovy, announces a major boardroom reshuffle. Get the inside scoop on the new faces and strategic direction.
Meet the trailblazing female entrepreneurs who built healthcare empires from scratch and are reshaping medical innovation worldwide. Discover their inspiring journeys to billions.
Delhi Police uncovers how Nigerian drug cartels are recruiting Indian students from pharma colleges, providing specialized training, and creating sophisticated dispatch systems to smuggle narcotics globally.
Expert analysis compares Zydus Lifesciences and Rubicon Research in the booming Indian pharmaceutical sector. Discover key financial metrics, growth drivers, and investment outlook for these promising stocks.
India's pharmaceutical sector gears up for Q2 FY25 with projected 5-7% revenue growth, navigating US pricing pressures and domestic GST reductions while maintaining stable profitability.
In a major breakthrough, Narcotics Control Bureau uncovers sophisticated drug manufacturing unit in Madhya Pradesh's Ratlam district. Highly educated pharma graduates among those arrested in interstate narcotics operation.
India mandates safety QR codes on all essential medicines in public healthcare, transforming drug safety and combating counterfeit drugs with digital innovation.
Madhya Pradesh's Special Investigation Team gears up for significant arrests in the Sresan Pharma cough syrup case that claimed young lives. Exclusive details on the expanding investigation.
In a landmark judgment, India's Supreme Court allows Natco Pharma to produce affordable generic version of Roche's expensive spinal muscular atrophy treatment, making life-saving therapy accessible to thousands.